Hutch Spinoff Presage Biosciences Shuffles Management

Xconomy Seattle — 

Seattle-based Presage Biosciences, a spinoff from the Fred Hutchinson Cancer Research Center, is making some leadership changes.

CEO Caitlin Cameron has resigned, and is being replaced on an interim basis by Jim Towne, an investor in the company who was briefly president of Microsoft in its early days. Nathan Caffo, Presage’s vice president of business development, will take on additional responsibility as interim president, according to founder Jim Olson.

Presage, founded by Olson at the Hutch in November 2008, has raised more than $5 million to develop a tool to help drugmakers predict which drugs are likely to succeed in clinical trials.